Case report

Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report

Eric Jacobsen¹, Jey-Hsin Chen², Brian Schurko¹, Carol Benson³ and William K Oh¹*

Addresses: ¹Mount Sinai School of Medicine, One Gustave L. Levy Place - Box 1079 New York, NY 10029, USA
²Massachusetts General Hospital, Boston, MA, 55 Fruit St, Boston, MA 02114, USA
³Brigham and Women’s Hospital, Boston, MA, 75 Francis St, Boston, MA 02115, USA

Email: EJ - edjacobsen@partners.org; JHC - jeyhchen@iupui.edu; BS - brian_schurko@dfci.harvard.edu; CB - cbenson@partners.org; WKO* - william.oh@mssm.edu

* Corresponding author

Received: 15 April 2009  Accepted: 23 July 2009  Published: 19 August 2009


This article is available from: http://casesjournal.com/casesjournal/article/view/7273

© 2009 Jacobsen et al.; licensee Cases Network Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

An asymptomatic 67-year-old man presented with a left supraclavicular lymph node that enlarged over a 2-month period which was biopsied. Pathologic features were consistent with involvement by metastatic seminoma and follicular lymphoma, follicular pattern, grade 1 (of 3). Staging Positron Emission Tomography/Computed Tomography scans indicated several areas of enlarged lymph nodes. The patient completed chemotherapy with bleomycin, etoposide, and cisplatin chemotherapy. This is the first reported case of metastatic seminoma and follicular lymphoma occurring in the same lymph node. No obvious pathophysiologic link exists between these two malignancies and there are no shared common risk factors. Given the natural history of these two malignancies, if this patient develops recurrent lymphadenopathy, it will be difficult to identify whether the enlarged lymph nodes represent recurrent seminoma or follicular lymphoma without a biopsy of each pathologically enlarged node. Similarly, Fluorodeoxyglucose- Positron Emission Tomography is known to be active in both seminoma and follicular lymphoma, making this scan non-specific in this patient. Finally, this patient had no baseline elevation in any germ cell tumor marker. Thus, serum tumor markers cannot be relied upon as surrogates for response to chemotherapy or as identifiers of relapsed seminoma.

Case presentation

An asymptomatic 67-year-old white, American man presented with a left supraclavicular lymph node that enlarged over a 2-month period. His primary care physician recommended a biopsy.

The left supraclavicular lymph node was partially effaced by neoplastic nodules of small lymphocytes with cleaved nuclei and scant cytoplasm intermixed with rare centroblasts, and by metastatic seminoma which is associated with a non-necrotizing granulomatous reaction (Figure 1a, b). The neoplastic lymphocytes were positive for CD20 (Figure 1c) and CD10 (Figure 1d) and showed monotypic surface immunoglobulin lambda light chain expression by flow cytometric analysis. The anti-apoptotic marker bcl-2 (Figure 1e) was reactive in a subset of the...
follicles. The seminoma cells were positive for c-kit (Figure 1f) and negative for keratin and for melanocytic and lymphocytic markers (not shown). The overall features were consistent with involvement by metastatic seminoma and follicular lymphoma, follicular pattern, grade 1 (of 3).

The patient had no fevers, chills, night sweats, unintentional weight loss, or other systemic symptoms. He had not noted any testicular masses or pain. He was not experiencing shortness of breath or cough. His past medical history was notable only for benign prostatic hypertrophy, with a prostate biopsy showing no evidence of malignancy, and Dupuytren’s contracture of the right hand.

Physical examination was notable for a healed left supraclavicular lymphadenectomy scar, no other palpable lymph nodes and a slightly atrophic left testis with no palpable testicular masses. A serum prostate-specific antigen (PSA) was 3.23 ng/ml, serum beta-human chorionic gonadotrophin (HCG) was undetectable, and a serum alpha-fetoprotein (AFP) was 4.2 ng/ml (normal range 0-7.6 ng/ml). Serum LDH was 389 u/l (normal range 313-618 u/l). A complete blood count with differential, serum electrolytes, renal function, and liver function were all within normal limits.

A scrotal ultrasound demonstrated a mildly heterogeneous and small (2.6 × 1.3 × 2.2 cm) left testicle consistent with atrophy as well as a small left varicocele. The right testicle was normal (3.6 × 2.5 × 1.8 cm). Positron emission tomography (PET) and computed tomography (CT) scan performed approximately one month after the original CT scan demonstrated FDG uptake in left supraclavicular (1.5 × 0.8 cm), bilateral axillary (1.6 × 1.0 cm on left, 1.5 × 1.1 cm on right), anterior mediastinal (without CT correlate), retroperitoneal (1.5 × 1.9 cm), and mesenteric (1.6 × 1.0 cm) lymph nodes. The prostate gland was slightly enlarged and exhibited mild FDG uptake.

This is the first reported case of metastatic seminoma and follicular lymphoma occurring in the same lymph node. We are aware of a report of metachronous seminoma and Hodgkin’s disease [1]. No obvious pathophysiologic link exists between these two malignancies and there are no shared common risk factors. The patient completed chemotherapy with bleomycin, etoposide, and cisplatin (BEP) and remains in complete remission over three years later [2]. He had no specific testicular primary noted, but did have an atrophic left testis which could have represented a “burnt out” primary. Although his lymphoma did not require therapy, these agents are also active in lymphoid malignancies [3]. This may make evaluation of response and monitoring for relapse difficult, as both seminoma and follicular lymphoma would be expected to respond to BEP. However, follicular lymphoma will inevitably relapse after chemotherapy whereas seminoma has a high cure rate in this setting. If this patient develops recurrent lymphadenopathy, it will be difficult to know whether the enlarged lymph nodes represent recurrent seminoma or follicular lymphoma without a biopsy of each pathologically enlarged node. Similarly, FDG-PET is known to be active in both seminoma and follicular lymphoma, making this scan non-specific in this patient [4,5]. Finally, this patient had no baseline elevation in any germ cell tumor marker. Thus, serum tumor markers cannot be relied upon as surrogates for response to chemotherapy or as identifiers of relapsed seminoma.

**Abbreviations**

FDG, fluorodeoxyglucose; HCG, Human chorionic gonadotropin; LDH, lactate dehydrogenase; PSA, prostate specific antigen.

**Consent**

Written informed consent was obtained from the patient for publication of this case report and accompanying
images. A copy of the written consent is available for review from the journal’s Editor-in-Chief.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
WKO was one of the patient’s clinician, gathered and analyzed data, and contributed in writing the manuscript. EJ was one of the patient’s clinician and helped gather data. JHC reviewed all tissue slides from the patient’s biopsy and contributed in writing the manuscript. BS gathered all data from clinicians and was a major contributor in writing the manuscript. CB reviewed all radiological scans of the patient. All authors read and approved the final manuscript.

References

Do you have a case to share?
Submit your case report today
- Rapid peer review
- Fast publication
- PubMed indexing
- Inclusion in Cases Database

Any patient, any case, can teach us something

www.casesnetwork.com